These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10779023)

  • 1. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas.
    Marina NM; Poquette CA; Cain AM; Jones D; Pratt CB; Meyer WH
    J Pediatr Hematol Oncol; 2000; 22(2):112-8. PubMed ID: 10779023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
    Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
    J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
    Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Thomas D; Sylvester R; Van Oosterom A
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S13-6. PubMed ID: 3102089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide nephrotoxicity in paediatric cancer patients.
    Ashraf MS; Brady J; Breatnach F; Deasy PF; O'Meara A
    Eur J Pediatr; 1994 Feb; 153(2):90-4. PubMed ID: 8157032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide in pediatric solid tumors.
    Carli M; Passone E; Perilongo G; Bisogno G
    Oncology; 2003; 65 Suppl 2():99-104. PubMed ID: 14586158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
    J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
    J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome--a report of two cases.
    Rossi R; Helmchen U; Schellong G
    Eur J Pediatr; 1992 May; 151(5):384-7. PubMed ID: 1396897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
    Stern N; Sakji I; Defachelles AS; Lervat C; Ryckewaert T; Marliot G; Peugniez C; Deplanque D; Penel N
    Bull Cancer; 2017 Mar; 104(3):208-212. PubMed ID: 27986268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
    Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Verwey J; Dombernowsky P; Onsrud M; Thomas D; Sylvester R
    Eur J Cancer Clin Oncol; 1987 Mar; 23(3):311-21. PubMed ID: 3595691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
    Heideman RL; Douglass EC; Langston JA; Krischer JP; Burger PC; Kovnar EH; Kun LE; Friedman HS; Kadota R
    J Neurooncol; 1995; 25(1):77-84. PubMed ID: 8523093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
    Buesa JM; López-Pousa A; Martín J; Antón A; García del Muro J; Bellmunt J; Arranz F; Valentí V; Escudero P; Menéndez D; Casado A; Poveda A
    Ann Oncol; 1998 Aug; 9(8):871-6. PubMed ID: 9789610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
    Meyer WH; Pratt CB; Poquette CA; Rao BN; Parham DM; Marina NM; Pappo AS; Mahmoud HH; Jenkins JJ; Harper J; Neel M; Fletcher BD
    J Clin Oncol; 2001 Jan; 19(1):171-82. PubMed ID: 11134210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.